Skip to main content

Table 3 HR (95% CI) of stratified analysis across tertiles of serum choline levels

From: Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study

 

Liver cancer-specific survival

Overall survival

 

T1

T2

T3

P-trend

P-interaction

T1

T2

T3

P-trend

P-interaction

Sexa, b

    

0.511

    

0.781

 Men

1.00

0.77 (0.56–1.07)

0.66 (0.48–0.92)

0.013

 

1.00

0.80 (0.58–1.10)

0.71 (0.52–0.98)

0.037

 

 Women

1.00

1.21 (0.41–3.52)

1.59 (0.57–4.44)

0.360

 

1.00

1.15 (0.42–3.14)

1.33 (0.50–3.54)

0.567

 

Agea, b, years

    

0.838

    

0.801

  < 60

1.00

1.03 (0.72–1.48)

0.69 (0.48–0.99)

0.031

 

1.00

1.07 (0.75–1.52)

0.74 (0.52–1.06)

0.070

 

  ≥ 60

1.00

0.80 (0.42–1.51)

0.63 (0.34–1.17)

0.142

 

1.00

0.83 (0.45–1.53)

0.65 (0.36–1.18)

0.155

 

BMIa, b, kg/m2

    

0.357

    

0.436

  < 25.0

1.00

0.90 (0.64–1.27)

0.74 (0.53–1.04)

0.079

 

1.00

0.88 (0.62–1.23)

0.77 (0.55–1.07)

0.117

 

  ≥ 25.0

1.00

1.15 (0.54–2.44)

0.47 (0.20–1.10)

0.118

 

1.00

1.03 (0.50–2.12)

0.61 (0.28–1.32)

0.185

 

Smoking statusa, b

    

0.820

    

0.756

 Smoker

1.00

0.58 (0.39–0.85)

0.57 (0.39–0.83)

0.010

 

1.00

0.61 (0.42–0.89)

0.61 (0.42–0.88)

0.013

 

 Non-smoker

1.00

1.17 (0.69–1.98)

0.85 (0.50–1.42)

0.481

 

1.00

1.19 (0.71–2.01)

0.91 (0.55–1.51)

0.669

 

Drinking statusa, b

    

0.388

    

0.399

 Drinker

1.00

0.67 (0.41–1.07)

0.78 (0.50–1.22)

0.342

 

1.00

0.71 (0.44–1.13)

0.75 (0.48–1.16)

0.237

 

 Non-Drinker

1.00

1.23 (0.82–1.86)

0.72 (0.47–1.12)

0.077

 

1.00

1.16 (0.77–1.74)

0.74 (0.49–1.13)

0.135

 

AFP levela, b, ng/mL

    

0.160

    

0.566

  ≥ 400

1.00

0.85 (0.56–1.30)

0.80 (0.52–1.22)

0.300

 

1.00

0.86 (0.57–1.29)

0.83 (0.56–1.25)

0.385

 

  < 400

1.00

0.87 (0.55–1.37)

0.68 (0.43–1.06)

0.085

 

1.00

0.91 (0.58–1.42)

0.73 (0.48–1.13)

0.155

 

CRP levela, b, mg/L

    

0.010

    

0.005

  ≥ 3.0

1.00

0.91 (0.64–1.29)

0.60 (0.41–0.88)

0.008

 

1.00

0.92 (0.65–1.29)

0.63 (0.44–0.91)

0.013

 

  < 3.0

1.00

1.34 (0.70–2.56)

1.37 (0.74–2.51)

0.353

 

1.00

1.34 (0.71–2.54)

1.47 (0.81–2.67)

0.224

 

Serum folate levela, b

    

0.782

    

0.946

 High

1.00

1.07 (0.67–1.70)

0.79 (0.50–1.26)

0.279

 

1.00

1.17 (0.74–1.84)

0.91 (0.58–1.43)

0.583

 

 Low

1.00

0.96 (0.62–1.47)

0.77 (0.50–1.17)

0.207

 

1.00

0.94 (0.62–1.42)

0.76 (0.50–1.14)

0.170

 

Liver damage levela, b

    

0.520

    

0.602

 1

1.00

1.39 (0.34–5.74)

1.54 (0.40–6.00)

0.547

 

1.00

1.85 (0.52–6.62)

1.16 (0.34–3.97)

0.935

 

 2

1.00

1.06 (0.63–1.78)

0.58 (0.33–1.01)

0.045

 

1.00

1.06 (0.63–1.78)

0.65 (0.38–1.13)

0.114

 

  ≥ 3

1.00

0.82 (0.55–1.22)

0.72 (0.48–1.08)

0.115

 

1.00

0.86 (0.58–1.26)

0.78 (0.53–1.14)

0.206

 

Presence of fatty livera, b

    

0.385

    

0.842

 Yes

1.00

1.08 (0.38–3.07)

0.94 (0.32–2.78)

0.902

 

1.00

1.05 (0.40–2.76)

1.17 (0.45–3.03)

0.741

 

 No

1.00

0.94 (0.68–1.30)

0.69 (0.50–0.97)

0.026

 

1.00

0.96 (0.70–1.32)

0.72 (0.52–0.99)

0.035

 

Presence of cirrhosisa, b

    

0.518

    

0.170

 Yes

1.00

0.93 (0.60–1.43)

0.83 (0.54–1.27)

0.380

 

1.00

0.93 (0.61–1.42)

0.90 (0.60–1.35)

0.602

 

 No

1.00

0.98 (0.63–1.52)

0.63 (0.39–1.00)

0.048

 

1.00

1.01 (0.66–1.56)

0.62 (0.39–0.98)

0.039

 

BCLC stagea, b

    

0.774

    

0.502

 0/A

1.00

0.80 (0.34–1.90)

0.72 (0.32–1.62)

0.440

 

1.00

0.91 (0.40–2.11)

0.78 (0.35–1.73)

0.515

 

 B/C

1.00

0.89 (0.64–1.23)

0.64 (0.46–0.90)

0.008

 

1.00

0.88 (0.63–1.21)

0.67 (0.48–0.93)

0.014

 

Treatmenta, b

    

0.333

    

0.480

 Liver resection

1.00

1.29 (0.69–2.41)

0.81 (0.42–1.56)

0.536

 

1.00

1.16 (0.63–2.14)

0.87 (0.46–1.62)

0.664

 

 Intervention

1.00

0.75 (0.51–1.10)

0.60 (0.41–0.86)

0.006

 

1.00

0.80 (0.55–1.17)

0.64 (0.45–0.92)

0.015

 

 Others

1.00

1.26 (0.52–3.07)

0.95 (0.37–2.42)

0.908

 

1.00

1.21 (0.49–2.94)

1.00 (0.40–2.50)

0.985

 
  1. a Covariates adjusted for age, sex, BMI, education level, smoking status, baseline liver damage level, BCLC stage, treatment, AFP level and CRP level
  2. b Stratified factors were not included in the corresponding models